Αποτελέσματα Αναζήτησης
KALA BIO is a clinical-stage biopharmaceutical company developing innovative therapies based on mesenchymal stem cell secretome (MSC-S) for rare and serious eye diseases. The company has two FDA-approved ophthalmic products and a pipeline of MSC-S products for ocular surface and retinal diseases.
- Our Technology
Kala Pharmaceuticals - Our Technology. BIOLOGICS FOR RARE...
- Pipeline
KALA BIO is advancing an innovative pipeline based on its...
- Leadership
Mr. Rosen is also currently a member of the board of...
- Investors
©2023 KALA BIO All rights reserved. September 2023. Terms of...
- Get in Touch
Kala Pharmaceuticals, Inc. 1167 Massachusetts Avenue...
- Press Releases
KALA BIO Reports Second Quarter 2024 Financial Results and...
- SEC Filings
Sep 06, 2024: 424B5: Form of prospectus disclosing...
- Stock Quote & Chart
The Investor Relations website contains information about...
- Our Technology
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United...
Kala Pharmaceuticals - Our Technology. BIOLOGICS FOR RARE OPHTHALMIC CONDITIONS. Our focus is the advancement of product candidates based on our proprietary mesenchymal stem cell secretome (MSC-S) platform which we believe could address key unmet medical needs for rare corneal and retinal diseases.
27 Οκτ 2020 · Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease. October 27, 2020. PDF Version. -- First Approved Prescription Therapy Specifically for Short-Term Treatment of Dry Eye Disease -- -- First Ocular Corticosteroid Indicated for Dry Eye Disease -- -- Kala to Host ...
15 Νοε 2021 · Kala Pharmaceuticals, a biopharmaceutical company focused on eye diseases, acquires Combangio, a clinical-stage company developing KPI-012, a novel secretome therapy for PCED and other ocular surface diseases. KPI-012 is a topical ocular solution that demonstrated positive safety and efficacy results in a Phase 1b trial and is expected to enter Phase 2/3 trial in 2022.
27 Δεκ 2022 · Kala Pharmaceuticals is a biopharmaceutical company developing innovative therapies for rare eye diseases. It announced that the FDA accepted its IND application for KPI-012, a human mesenchymal stem cell secretome, for persistent corneal epithelial defect (PCED), a rare condition of impaired corneal healing.
28 Νοε 2022 · Kala is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye. Kala’s biologics-based investigational therapies utilize Kala’s proprietary Mesenchymal Stem Cell Secretome (MSC-S) platform.
